In the TOPCAT study, spironolactone therapy did not reduce death from cardiovascular causes, aborted cardiac arrest, or hospitalization of patients with heart failure and preserved ejection fraction. In a post hoc analysis, the TOPCAT investigators examined the regional difference in clinical outcomes and responses to spironolactone within the study population. Compared with patients from Russia and Georgia, patients from the Americas had greater changes in potassium and creatinine levels in response to spironolactone treatment. Furthermore, the rates of the primary outcome were reduced by spironolactone in patients from the Americas, but not in patients from Russia and Georgia.
References
Pfeffer, M. A. et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 10.1161/CIRCULATIONAHA.114.0132.55
Rights and permissions
About this article
Cite this article
Regional patient variability and outcomes in TOPCAT. Nat Rev Cardiol 12, 5 (2015). https://doi.org/10.1038/nrcardio.2014.197
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2014.197